Join us in Philadelphia from Sept. 25-27th for our "Together We Will" Weekend: - Register today!

The Desmoid Tumor Research Foundation

August 2021

The safety and ablation efficacy of ultrasound-guided high-intensity focused ultrasound ablation for desmoid tumors

Author Information

Zhang R (1), Chen JY(1), Zhang L (1), Li KQ (2), Xiao ZB (3), Mo SJ (1), Chen L (2), Chen WZ (1,2).

(1) State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical Univ, Chongqing, PR China, (2) Dept of Surgery, Chongqing Haifu Hosp, Chongqing, PR China, (3) Dept of Radiology, The First Affiliated Hosp of Chongqing Medical University, Chongqing, PR China.

Publication

Int J Hyperthermia.

Summary

Objective: To evaluate the safety and efficacy of ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation for desmoid tumors (DTs). Method: A total of 111 patients with histologically proven DTs were included and treated by USgHIFU ablation. Adverse events were continuously evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 until 3 months after treatment. The incidence of non-perfused areas within the treated tumors, non-perfused volume rate (NPVR) and tumor volume reduction were evaluated using contrast-enhanced MRI before and one week and 3 months after the procedure. Results: The enrolled patients (32 male, 79 female, mean age 29.5 ± 1.0 years) with 145 DTs (118 extra-abdominal, 16 abdominal wall, 11 intra-abdominal; median maximum diameter: 9.6 cm, range: 3-34.5 cm) underwent 188 sessions of HIFU ablation, and the mean number of ablations was 1.7 (range, 1-7) per patient. In majority of cases (143/145 cases, 98.6%), no serious adverse events were observed. There was no significant difference in the incidence of adverse events between patients who received a single treatment and those who received multiple treatments. Non-perfused area was observed within every treated tumor, and the median NPVR was 84.9% (range, 1.9-100%). The tumor volume reduction rate was 36.1 ± 4.2% at 3 months after treatment. Conclusion: USgHIFU ablation, as a noninvasive and easily repeatable local treatment, is a promising treatment for DTs.

View Abstract